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Abstract
Medulloblastoma is the most frequent malignant pediatric brain tumor with a dismal prognosis in 30% of cases. We
examined the activity of AEE788, a dual inhibitor of human epidermal receptor (HER) 1/2 and vascular endothelial
growth factor receptor (VEGFR) 1/2, in medulloblastoma preclinical models. Established lines (Daoy and D283),
chemoresistant (DaoyPt), and ectopically HER2-overexpressing (DaoyHER2) cells expressed diverse levels of total
and activated AEE788 target receptors. In vitro, AEE788 inhibited cell proliferation (IC50 from 1.7 to 3.8 μM) and
prevented epidermal growth factor– and neuregulin-induced HER1, HER2, and HER3 activation. Inhibition of Akt
paralleled that of HER receptors. In vivo, AEE788 growth inhibited Daoy, DaoyPt, and DaoyHER2 xenografts by
51%, 45%, and 72%, respectively. Immunohistochemical analysis of mock- and HER2-transfected xenografts re-
vealed that the latter showed, along with high HER2 expression, high VEGFR2 staining in tumor and endothelial cells
and increased expression of the endothelial marker CD31. AEE788 reduced the activation of target receptors and
angiogenesis. In 21 primary medulloblastoma, HER2 expression significantly correlated (P< .01) with VEGFR2 ( r=
0.56) and VEGF (r = 0.61). In conclusion, AEE788 shows similar growth-suppressive activities in chemosensitive
and chemoresistant medulloblastoma cells in vitro and in vivo. Ectopic HER2 overexpression sensitizes cells to
AEE788 in vivo, but not in vitro, possibly through host-mediated processes. Together with the experimental data,
the finding that HER2 positively correlates with VEGFR2 and VEGF in human medulloblastoma specimens indicates
HER2-overexpressing medulloblastoma as the subset that most likely might benefit from AEE788 treatment.
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Introduction
Medulloblastoma is the most common malignant brain tumor of
childhood [1]. Despite intensive treatment, approximately 30% of
children with medulloblastoma die of their disease, whereas survivors
often experience long-term iatrogenic sequelae [2]. New agents that are
more effective and less toxic should be developed.
As long as the molecular bases of tumorigenesis increase, new ave-
nues for treating cancer are being explored. Because of the interplay
between signaling pathways in tumor and tumor-associated cells, the
single-targeted molecular agents are giving the way to agents able to
concurrently inhibit multiple targets and biologic processes [3]. Aber-
rant signals through receptor tyrosine kinases, including those of the
human epidermal receptor (HER) family, activate proliferation and
prosurvival pathways that confer selective growth advantage to tumor
cells [4]. In addition, tumor cells require the formation of new vessels
for nutrient and oxygen supplies [5]. Numerous ligands are involved in
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the coordinated processes that lead to angiogenesis, but vascular endo-
thelial growth factor (VEGF) seems to play a pivotal role in controlling
mitogenesis and survival of endothelial cells [6]. VEGF binds to both
VEGF receptor 1 (VEGFR1, Flt1) and VEGFR2 (KDR, Flk1) on the
surface of endothelial cells, VEGFR2 being, however, the main medi-
ator of VEGF signaling.
A functional link betweenHER family members and VEGF has been
established. Tumor cells can be stimulated by activation of HER1
(EGFR, ErbB1) to secrete VEGF, which, in turn, induces angiogenesis
through paracrine mechanisms [7]. HER2 (ErbB2/neu) has also been
associated with increased angiogenic potential in experimental and clin-
ical models. In breast cancer, HER2 signaling induced by ectopic over-
expression of HER2 or ligand stimulation increases VEGF expression
in vitro [8], and in biopsy specimens, HER2 expression positively cor-
relates with VEGF [9].
These data lend the experimental support for combined targeting
of HER- and VEGFR-dependent pathways in clinical settings [10].
One of the agents under development is AEE788, a member of the
7H -pyrrolo[2,3] class of pyrimidines, which inhibits tyrosine kinase
activity of HER1/2 and VEGFR1/2 with similar affinity, thus poten-
tially blocking both HER-driven proliferation of tumor cells and vas-
culature neoformation mediated by VEGFRs [11]. AEE788 has
demonstrated antiproliferative activity against cell lines and xeno-
grafts from different tumors, such as carcinomas of lung, prostate,
thyroid, and colon [11–13]. Clinical trials with AEE788 in tumors,
including those of the brain, are ongoing, and results are awaited
(www.clinicaltrials.gov).
Medulloblastoma might be a candidate for AEE788 treatment be-
cause of the expression of AEE788-sensitive targets in this tumor.
Particularly, HER2 increases angiogenic potential in medulloblastoma
preclinical models [14], and HER2 is overexpressed in a sizable sub-
population of patients, being associated with more aggressive disease,
poor survival, and chemoresistance [15]. VEGF receptors and ligands
are coexpressed in medulloblastoma cells and patient samples, suggesting
an autocrine role for this loop in medulloblastoma tumorigenesis [16].
In the present study, we investigated the therapeutic potential of
AEE788 in medulloblastoma by using commercially available medul-
loblastoma lines, cells with acquired drug resistance, and cells with
ectopic expression of HER2. We found that AEE788 inhibits the
proliferation of medulloblastoma lines and that chemoresistance is
not associated with resistance to AEE788 in vitro and in vivo. In xeno-
grafts, ectopic HER2 overexpression increases VEGFR2 expression in
tumor cells and angiogenesis and results in a greater response to
AEE788 antitumor activity. In primary human medulloblastoma,
HER2 expression significantly correlates (P < .01) with the expression
of VEGF and VEGFR2. Together, these data suggest that AEE788
might have a therapeutic potential in medulloblastoma, identifying
HER2 as a possible predictive marker of responsiveness to the agent.
Materials and Methods
Reagents
AEE788 (kindly provided by Novartis Pharmaceuticals, Basel,
Switzerland) was dissolved in dimethyl sulfoxide to a 10-mM stock
solution. For oral administration, AEE788 was dissolved immediately
before use in N -methylpyrrolidone and polyethylene glycol 300 (1:9;
Sigma, Dorset, UK).
The following primary antibodies were used: HER1, p-HER1
(Tyr1173), and actin from Santa Cruz Biotechnology (Santa Cruz,
CA); p-HER2 (Tyr1248 ) from Upstate Biotechnology (Lake Placid,
NY); and HER2, p-HER3 (Tyr1289), Akt, p-Akt (Ser473), extracellular
signal–regulated kinase (ERK) 1/2, p-ERK1/2 (Thr202/Tyr204), VEGFR2
from Cell Signaling Technology (Beverly, MA) for Western blot analy-
sis. For immunohistochemistry, the following primary antibodies were
used: HER1, p-HER1 (Tyr1173) (Santa Cruz Biotechnology), HER2,
p-HER2 (Tyr1221/1222), VEGFR2, p-VEGFR2 (Tyr1175, Cell Signaling
Technology), and antimouse CD31 (BD PharMingen, SanDiego, CA).
Horseradish peroxidase–conjugated secondary antibodies were from
Vector (Burlingame, CA).
Cell Lines and Culture Conditions
The human medulloblastoma cell lines D283 and Daoy were ob-
tained from American Type Culture Collection (Rockville, MD).
D283 cells were grown according to the American Type Culture Collec-
tion’s recommendations. Cisplatinum-resistant DaoyPt cells were estab-
lished by continuous exposure to stepwise-increasing concentrations of
cisplatinum up to 1.5 μM. For HER2 overexpression, Daoy cells were
transfected with either pcDNA3.1 empty vector or pcDNA3.1-HER2
expression vector and selected under 100 μg/ml of G418 (Sigma) [17].
Daoy cells and derivatives were maintained in 10% fetal bovine serum
(FBS)/RPMI supplementedwith L-glutamine, a penicillin/streptomycin
mixture (Sigma), and the appropriate selecting agent that was removed
at least 1 week before any experiment was performed.Different clones of
HER2-overexpressingDaoy cells were used giving similar results. There-
fore, only data from clone no. 20, called DaoyHER2, have been reported.
Daoy transfected with empty vector (DaoyV) behaved as untransfected
Daoy cells.
Cell Viability Assay
Cell viability assays with AEE788 were performed in 2% FBS-
containing medium, as previously reported [11,12]. Cells were seeded
into six-well tissue culture plates at the appropriate density to prevent
confluence throughout the experiment. After 24 hours, cells were ex-
posed to vehicle or increasing concentrations of AEE788 for 72 hours.
Viable cells as judged by trypan dye exclusion were counted and ex-
pressed as a percent of the control. IC50 values were then determined
by mathematical curve fitting by using CalcuSyn for Windows soft-
ware package (Biosoft, Cambridge, UK).
RNA Preparation and Reverse Transcription–Quantitative
Polymerase Chain Reaction
Total RNA was extracted from cells using TRIzol (Invitrogen Corp,
Paisley, UK) according to the manufacturer’s protocol. One microgram
of total RNA was reverse-transcribed with Moloney murine leukemia
virus reverse transcriptase and random primers (Invitrogen Corp). Gene
expression was quantified by real-time quantitative polymerase chain
reaction (qPCR) performed on a 7500 Real-time PCR Systems (Ap-
plied Biosystems, Foster City, CA). PCRs were done using Applied
Biosystems Master Mix reagents as per manufacturer’s instructions.
TaqMan gene expression assays forHER1,HER2, VEGFR2, and VEGF
and the reference normalization gene hypoxanthine guanine phospho-
rybosyltransferase (HPRT ) were obtained from Applied Biosystems.
Each amplification reaction was performed in triplicate, and the average
of the three threshold cycles (Ct) of each gene was normalized to that of
HPRT for each sample to get ΔCt (ΔCt = Cttarget gene − CtHPRT ). The
ΔCt was then converted to the relative amount of tissue target messen-
ger RNA (mRNA) by the formula 2−ΔCt.
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Ligand Stimulation and Western Blot Analysis
For ligand stimulation, 80% confluent cells were starved overnight in
0.5% FBS medium. Cells were then exposed to AEE788 (0.1-5 μM)
for 2 hours and subsequently stimulated for 10 minutes with 25 ng/ml
epidermal growth factor (EGF; Sigma) or 50 ng/ml neuregulin (NRG;
Sigma). At the end of treatment, cells were scraped in lysis buffer
(20 mM Tris [pH 7.4], 150 mM NaCl, 1% Nonidet P-40, 1 mM
EDTA, 1 mM EGTA, 1 mM sodium orthovanadate, 10 mM sodium
fluoride, 1 μg/ml leupeptin, 1 μg/ml aprotinin, 1 μg/ml pepstatin, and
1 mM phenylmethylsulfonyl fluoride). Total lysates were subjected
to electrophoresis on 8% to 10% polyacrylamide gels, transferred to
a Hybond nitrocellulose membrane (Amersham Pharmacia, Bucking-
hamshire, UK), and probed with appropriate dilutions of primary
antibodies. After incubating with horseradish peroxidase–conjugated
secondary antibodies, immunoblots were visualized using the ECL de-
tection system (Amersham Pharmacia).
Animals and Tumor Growth Inhibition Studies
All animal investigations complied with the guidelines of the Istituto
Superiore di Sanità (Rome, Italy) on experimental neoplasia in animals.
Medulloblastoma cells (20 × 106) were injected subcutaneously together
with an equal volume of Matrigel (Becton Dickinson, Franklin Lakes,
NJ) in both flanks of athymic nude mice (Charles River, Calco, Italy).
Mice were randomly divided into two groups of 10 animals per group,
and either vehicle or 50mg/kg AEE788 was administered orally thrice a
week for 4weeks. Tumor volume (TV) and total weight weremonitored
every 3 days. TVs were calculated by the formula: TV = d2 ×D/2, where
d andD are the shortest and longest diameters, respectively. The efficacy
of drug treatment was assessed as percentage tumor volume inhibition
(TVI) in treated (T ) versus control (C ) mice according to the formula:
TVI = 100 − (T /C × 100). Two-tailed Student’s t tests were applied to
compare tumor growth between treated and control groups; the differ-
ences were considered statistically significant at P < .05.
Immunohistochemistry
Xenograft specimens were fixed with 4%paraformaldehyde, paraffin-
embedded, and cut into 3-μm sections. Sections were deparaffinized,
and endogenous peroxidase was blocked with 3% hydrogen peroxide
in phosphate buffer. After microwaving sections in the appropriate
buffer for antigen retrieval, nonspecific protein binding was blocked
with 20% normal goat/rabbit serum. Sections were incubated over-
night at 4°C with primary antibodies at the following working dilutions:
1:100 for p-HER1, HER1, p-VEGFR2, and CD31; 1:50 for p-HER2;
1:150 for VEGFR2; and 1:500 forHER2. Sections were then incubated
with the secondary anti–mouse/rabbit/goat EnVision System-HRP
(DakoCytomation, Carpinteria, CA) for 30 minutes at room tempera-
ture. After washing, the signal was detected by EnVisionr+ System–
horseradish peroxidase (DakoCytomation) as per the manufacturer’s
instructions. Slides were counterstained with Mayer hematoxylin and
were finally mounted. Immunohistochemical staining for CD31 was
by the streptavidin-biotin peroxidase method using the Vectastatin
ABC system (Vector).
Reverse Transcription–qPCR Analysis of Human
Medulloblastoma
Surgical specimens of primary medulloblastoma (6 desmoplastic,
12 classic, and 3 anaplastic/large cells, according to the World Health
Organization’s criteria) were collected from 13 male and 8 female pa-
tients with institutional review board approval. Tumor samples were
snap-frozen in liquid nitrogen in the operating room and then stored in
liquid nitrogen until further analysis. Total RNA was extracted using
RNeasy Kit (Qiagen, Venlo, NE) and retrotranscribed with random
primers. Complementary DNA quality was confirmed by PCR analysis
of β-actin internal control expression. Real-time qPCR analysis was
performed as described to determine the expression level of HER2,
VEGFR2, VEGFR1, VEGF, basic fibroblast growth factor (bFGF), trans-
forming growth factor α (TGFα), and HPRT.
Statistical Analysis
Spearman correlation coefficients were calculated to assess associations
between the mRNA expression levels of the different genes. The statis-
tical significance level was set at P < .05. Calculations were performed
with SPSS software package, version 12.0 (SPSS, Inc, Chicago, IL).
Results
AEE788 Inhibits the Proliferation of Medulloblastoma
Cell Lines
In preliminary experiments, we characterized the response of Daoy
cells and derivatives to therapeutics commonly used in the treatment of
medulloblastoma. Cisplatinum-selected DaoyPt cells resulted 18-fold
resistant to cisplatinum and cross-resistant to carboplatinum and etopo-
side (10- and 4-fold, respectively; Figure 1A) compared with Daoy cells,
whereas HER2-overexpressing DaoyHER2 cells were significantly resis-
tant to cisplatinum and carboplatinum (4.9- and 2.1-fold, respectively)
but not to etoposide. DaoyV cells transfected with the empty vector
showed IC50 values similar to those of untransfected parental cells.
We next evaluated the growth-inhibitory effects of AEE788 in these
lines and in D283 cells. The proliferation of both D283 and Daoy cells
was inhibited by AEE788 in a dose-dependent manner, with IC50
values of 1.7 ± 0.1 and 3.8 ± 0.2 μM, respectively (P < .001; Figure 1B,
and data not shown). DaoyPt, DaoyHER2, and DaoyV cells did not show
a significantly different response to AEE788 compared with Daoy.
AEE788-Sensitive Targets Are Expressed and Activated at
Variable Levels in Medulloblastoma Cell Lines
We determined the expression of AEE788-sensitive targets in all
lines. D283 cells expressed high levels of HER2 mRNA and protein,
whereas Daoy cells showed high levels of HER1 (Figure 1, B and C).
Phosphotyrosine content paralleled the expression of the corresponding
receptor in each line. Phosphorylated (activated) and total HER1 was
undetectable with 1-minute exposure in D283 cells but showed a clear
signal with longer exposures (Figure 2B). DaoyPt cells displayed a recep-
tor profile similar to that of Daoy cells, whereas DaoyHER2 cells ex-
pressed 20-fold more HER2 mRNA and consistently higher levels of
total and activated protein.
Accordingly to previous data [16], our lines coexpressed VEGF and
VEGFR2 at mRNA levels (Figure 1D), with no substantial difference
in parental and derived Daoy cells. Total VEGFR2 protein was barely
detectable, whereas the activated form was not (Figure 1C , and data not
shown). To assess the relevance of VEGF/VEGFR2 as an autocrine/
paracrine loop in medulloblastoma, we compared the expression of
both genes in our lines to that in lines frommalignant glioma, a typically
angiogenic tumor that expresses in culture both VEGF and VEGFR2
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[18]. Reverse transcription (RT)–qPCR analysis demonstrated that both
genes were expressed at similar or higher amounts in medulloblastoma
compared with glioma lines (Figure 1D).
AEE788 Inhibits EGF-Induced Signaling in Medulloblastoma
Cell Lines
On binding to cognate ligands, receptor tyrosine kinases, including
HERs and VEGFRs, activate downstream Akt and ERK pathways that
promote cell proliferation and survival [4,6]. To determine the effects
of AEE788 on HER-mediated signaling, serum-starved medulloblas-
toma lines were treated with increasing concentrations of AEE788 for
2 hours and then stimulatedwith theHER1 ligandEGF for 10minutes.
In Daoy lines, HER1 and HER2 were activated by EGF and dose-
dependently inhibited by AEE788 (Figure 2A, and data not shown
for Daoy and DaoyPt cells). EGF increased also the phosphorylation
of Akt and ERK1/2, whose inhibition by AEE788 paralleled that of
HER1. Of note, Akt was still phosphorylated in baseline conditions
and was downregulated by 1 μM AEE788, suggesting the presence of
a constitutive, AEE788-sensitive activation of Akt in Daoy cells.
Overall, EGF induced a modest activation of HER1-mediated sig-
naling in D283 cells (Figure 2B). A slightly increased phosphorylation
was obvious only in HER1 and Akt proteins and was inhibited dose-
dependently by AEE788, whereas no modulation of p-ERK1/2 was
observed. HER2 was only minimally stimulated by EGF and reported
Figure 1. Antiproliferative effects of AEE788 and expression of AEE788-sensitive targets in medulloblastoma cell lines. (A) Sensitivity to
antineoplastic agents or AEE788 expressed as IC50 in Daoy, cisplatinum-selected DaoyPt, Daoy transfected with HER2 (Daoy
HER2) or empty
vector (DaoyV), and D283 cells. Viability assays were performed after 72 hours of treatment. *P< .01, **P< .001 compared with Daoy cells
(two-tailed Student’s t test). (B, D) RT-qPCR analysis of expression ofHER1 andHER2 (B) and VEGF and VEGFR2 (D) inmedulloblastoma lines
and in the glioma lines U87 and A172. Bars show means ± SD of three determinations of each target gene normalized to the endogenous
controlHPRT in each sample. (C) Expression levels of total and activated HER1, HER2, and VEGFR2 inmedulloblastoma cell lines. Cells were
serum-starved overnight in 0.5% FBS medium, and Western blot analysis was performed to either the total or the phosphorylated levels of
each protein. Equal loading was verified by actin immunoblot analysis. HUVEC cells were used as a positive control for VEGFR2 expression.
No phosphorylated VEGFR2 was detected. HUVEC indicates human umbilical vein endothelial cells.
Translational Oncology Vol. 3, No. 5, 2010 AEE788 in Medulloblastoma Preclinical Models Meco et al. 329
to the unstimulated levels by AEE788. However, AEE788 was not or
was scarcely effective in inhibiting constitutively active HER2 in both
DaoyHER2 and D283 lines. Expression of total HER1, HER2, Akt and
ERK1/2 proteins did not change throughout all of the experiments.
Because of the low level of VEGFR2 expression in our cell lines, we
were unable to induce its phosphorylation on stimulation with either
EGF or VEGF (data not shown). In contrast, DaoyHER2 growing
in vivo express high levels of VEGFR2 (see below).
AEE788 Inhibits NRG-Induced Signaling
We next investigated whether AEE788 could inhibit signaling trig-
gered by ligands other than EGF because D283 cells had little EGF-
induced activation despite their lowest IC50 for cellular growth. Among
ligands of the HER family, NRG has been reported to play a role in
medulloblastoma tumorigenesis [19]. NRG binds to the “kinase dead”
HER3 that preferentially signals as a complex with HER2, suggesting
that HER2 overexpression might sensitize cells to stimulation by NRG
[4]. DaoyV, DaoyHER2, and D283 cells were serum-starved, treated
with AEE788, and then stimulated with NRG and, for comparison,
with EGF. Unlike EGF, NRG did not activate either HER1 or HER2
over their basal level in DaoyV and DaoyHER2 cells, nor did it increase
the activity of Akt or ERK1/2 (Figure 3A). With respect to DaoyV,
DaoyHER2 cells displayed higher levels of ligand-independent
p-HER3, which were not further induced by either EGF or NRG. In
both lines, as little as 1 μM AEE788 reduced the level of HER3 phos-
phorylation below the baseline. By contrast, treatment with NRG, but
not EGF, caused a striking increase in HER3 activity in D283 cells,
with a concomitant marked activation of Akt, that was effectively pre-
vented by AEE788 (Figure 3B). Again, no phosphorylation of ERK1/2
was observed.
AEE788 Inhibits the Growth of Medulloblastoma Tumors
In Vivo
We compared the antitumor activity of AEE788 against Daoy,
DaoyPt, DaoyHER2, andDaoyV xenografts. AEE788 caused a statistically
significant reduction in tumor volume of Daoy and DaoyPt xenografts,
with a TVI of 51% and 45%, respectively (Figure 4, A and B). DaoyV
xenografts behaved as Daoy (data not shown). On the DaoyHER2 xeno-
grafts, AEE788 induced a more pronounced tumor inhibition (TVI =
72%; Figure 4C ). All the mice survived until the end of the 4-week
treatment period, with a less than 15% body weight loss at worst, which
was partially recovered by the end of the experiment (Figure 4, D-F ).
Because of the higher antitumor activity in DaoyHER2 xenografts, we
investigated the biologic effects of AEE788 in formalin-fixed specimens
from DaoyV and DaoyHER2 tumors at the end of treatment (Figure 5).
We evaluated the levels of expression and the phosphorylation status of
HER1, HER2, and VEGFR2. In both models, phosphorylated HER1
moderately decreased after treatment, consistently with a decrease in
the number of HER1-positive cells. Treated sections showed lympho-
cytic infiltration and microcystic areas, as a consequence of treatment,
as already observed in tumors from other tissues [20]. Expectedly,
DaoyHER2 xenografts exhibited a strong and diffuse immunopositivity
for HER2, whose phosphorylation levels were decreased by AEE788.
In these xenografts, an increase in immunoreactivity against VEGFR2
Figure 2. Inhibition of EGF-triggered signaling pathways in medulloblastoma lines by AEE788. DaoyV and DaoyHER2 (A) and D283 (B)
cells were serum-starved overnight and incubated with increasing concentrations of AEE788 2 hours before a 10-minute exposure to EGF
(25 ng/ml). Cell lysateswere subjected to immunoblot analysiswith antibodies to the phosphorylated and total HER1, HER2, Akt, and ERK1/2.
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was also evident, which localized to both endothelial cells of neoformed
vessels and tumor cells. In treated tumors, the level of staining was lower
because of both a reduction in the number of positive cells and staining
intensity.Overall, phosphorylatedVEGFR2was less intense than that of
total protein andwas reduced by treatment. To confirm neoangiogenesis
in DaoyHER2 xenografts, sections from tumors were stained with an
antibody against the endothelial marker CD31. Consistent with the
VEGFR2 data, a slight increase in CD31 immunoreactivity was only
detected in HER2-transfected cells and was reversed by treatment.
HER2 Expression Positively Correlates with VEGF and
VEGFR2 Expression in Human Medulloblastoma Specimens
To establish whether HER2 could be associated with angiogenesis in
clinical medulloblastoma, we evaluated the transcriptional expression
of angiogenesis-related genes in 21 fresh-frozen surgical samples by
RT-qPCR analysis. Therefore, we examined the expression of VEGF,
VEGFR2, VEGFR1, bFGF, and TGFα [5]. HER2 expression posi-
tively correlated with VEGF (r = 0.61, P < .01), VEGFR2 (r = 0.56,
P < .01), and bFGF (r = 0.60, P < .01) but not with VEGFR1 or TGFα
(Figure 6).
Discussion
In this study we show that AEE788 inhibits the proliferation of dif-
ferent medulloblastoma cell lines, including chemoresistant and
HER2-overexpressing cells, in vitro and in vivo, by interfering with
EGF- and NRG-mediated signaling pathways. Off-target inhibition
of HER3 contributes to AEE788 effects beyond its canonical targets,
potentially expanding AEE788’s therapeutic applications. In vivo, the
antitumor activity of AEE788 is increased in xenografts, with ectopic
overexpression of HER2, possibly because AEE788 inhibits both
HER2-induced angiogenesis and autocrine signaling mediated by
HER2 and de novo expression of VEGFR2 in tumor cells. These data,
together with the significantly positive correlation ofHER2 with VEGF
and VEGFR2 in human medulloblastoma samples, indicate HER2-
overexpressing medulloblastoma as the subset that might benefit most
from AEE788 treatment.
The sensitivity of medulloblastoma lines to AEE788 as expressed as
IC50 values ranged from ∼2 to 4 μM, values below the intratumoral
concentrations achievable in vivo [11], indicating that AEE788 could
be effective in medulloblastoma at clinically relevant doses. Our in vitro
results are in close agreement with those reported in cell lines from
other tumors [12,21,22]. However, this is the first report on AEE788
activity on cells with acquired resistance or ectopic overexpression of
HER2. Of note, HER2 signaling in our medulloblastoma cells resulted
in resistance to platinum compounds, and HER2 overexpression is as-
sociated with chemoresistance in medulloblastoma patients [15]. Pleo-
morphic drug resistance has previously been observed after transfection
of HER2 in tumor cells [23], and we found increased expression and
activation of endogenous HER2 in chemoresistant cells from glioma
and ovarian carcinoma [24]. Our in vivo experiments demonstrated
a similar (in Daoy and DaoyPt xenografts) or increased (in DaoyHER2
xenografts) antitumor activity of AEE788. Therefore, AEE788 proves
to be able to circumvent chemoresistance resulting from either contin-
uous exposure to drugs or HER2-mediated oncogenic signals, suggest-
ing that AEE788 could be as effective in chemo-naive as in pretreated
medulloblastoma patients.
AEE788 effectively prevented EGF-induced phosphorylation of
HER1 and transphosphorylation of HER2, concurrently blocking the
downstream signaling molecules Akt and ERK1/2. However, although
AEE788 is targeted to both HER1 and HER2 with similar affinity in
in vitro kinase assays [11], it was scarcely or not effective on constitutively
activated HER2, which spontaneously forms by ligand-independent
homodimerization in HER2-overexpressing cells [25]. Together, these
data indicate that AEE788’s inhibitory effects onHER2 phosphorylation
in cell-based assays could be mainly due to the blockade of transpho-
sphorylatingHER1 rather than to a direct effect onHER2kinase activity.
Another novel finding of our work is AEE788’s capability of blocking
NRG-dependent HER3 activation. On binding to NRG, the “kinase
dead” HER3 dimerizes with other HER receptors, preferably HER2
[4], functioning as a scaffold to activate the PI3K/Akt pathway because
of having multiple p85/p110a docking sites [26]. We found that NRG
strongly activated the HER3/PI3K/Akt route in D283 cells that dis-
play high levels of endogenousHER2, but it did not do so in DaoyHER2
cells. These data indicate that HER2 in the presence of highHER1 does
not redirect cells to NRG signaling and that the inhibitory effects of
AEE788 in these cells aremainly due to the blockade of EGF-dependent
Figure 3. Inhibition of NRG-induced signaling in medulloblastoma cells. DaoyV and DaoyHER2 (A) and D283 (B) cells were serum-starved
overnight and treated with the indicated concentrations of AEE788 2 hours before a 10-minute exposure to EGF (25 ng/ml) or NRG
(50 ng/ml). Cell lysates were subjected to immunoblot analysis with antibodies to the phosphorylated HER1, HER2, HER3, Akt, and ERK1/2.
Actin was used as a loading control.
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HER1 activation. By contrast, HER2 overexpression in the presence of
low HER1 might switch cells to an NRG-triggered HER3 pathway,
which is highly sensitive to inhibition by AEE788.
Although HER3 is not an easily drugable kinase because intrinsically
inactive, growing evidence shows that HER3 modulates the response
to inhibitors of the HER pathways in cell lines from different tumors
[26–28]. Given the importance of HER family trans-signaling in cancer
cell biology, research is directing toward agents able to simultaneously
inhibit HER1-, HER2-, and HER3-mediated pathways [29]. In this
light, AEE788’s therapeutic potential could be explored in new and
ampler clinical settings.
In vivo, but not in vitro, isogenic HER2 overexpression significantly
sensitized cells to AEE788 effects. This dissociation of in vitro and in vivo
efficacy is consistent with HER2 inducing host-mediated processes that
Figure 4. Antitumor activity of AEE788 on human medulloblastoma xenografts. Mice bearing Daoy (A), DaoyPt (B), and DaoyHER2 (C) xeno-
grafts received orally either vehicle only or AEE788 at a dosage of 50 mg/kg thrice a week for 4 weeks. Points shown are mean values for
groups of 8 to 10 mice. Bars, SE. Drug activity was defined by percentage TVI. (D-F) Effects of AEE788 treatment on the body weight
changes of animals bearing Daoy (D), DaoyPt (E), and DaoyHER2 (F) xenografts.
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Figure 5. Effects of AEE788 on the expression and phosphorylation/activation status of AEE788-sensitive targets in DaoyV and DaoyHER2
xenografts. Tumors were harvested and processed for immunohistochemical analysis at the end of treatment. Sections were stained for
expression of HER1, p-HER1, HER2, p-HER2, VEGFR2, p-VEGFR2 and CD31 (an endothelial cell marker), and counterstained with hematox-
ylin. Positive controls were as follows: breast cancer for HER1, p-HER1, and p-HER2; ovarian cancer for VEGFR2 and p-VEGFR2; endome-
trial cancer for HER2; and rat uterus for CD31. Comparedwith DaoyV xenografts, DaoyHER2 xenografts showed increased expression of total
and phosphorylated HER2 and VEGFR2 and of CD31. Treatment of mice with AEE788 decreased CD31 expression and the phosphorylation
of HER2 and VEGFR2. Original magnification, ×20.
Translational Oncology Vol. 3, No. 5, 2010 AEE788 in Medulloblastoma Preclinical Models Meco et al. 333
are sensitive to AEE788 inhibition. A greater tumor growth inhibition in
medulloblastoma xenografts with ectopic overexpression of HER2 has
previously been reported after treatment with HER inhibitors or anti-
angiogenesis agents [14,17] and almost exclusively ascribed to the block-
ade of the increased vascularization induced by HER2 [14]. In keeping
with these data, we found neoangiogenesis in DaoyHER2 xenografts as
detected by the expression of endothelial-associated VEGFR2 and
CD31 that were both reduced by treatment. However, direct effects
of AEE788 on tumor cells cannot be excluded. Indeed, AEE788 caused
a 50% TVI in Daoy xenografts, in which activation of HER1 signaling
only was observed in vivo and was inhibited by the drug. In DaoyHER2
xenografts, in addition to HER1 and HER2 activation, de novo ex-
pression of VEGFR2 in tumor cells might contribute to a prosurvival/
proliferation signaling in vivo because activated and total VEGFR2 were
easily detectable in xenografts but scarcely in vitro. Consistent with our
observation, colon carcinoma cells growing in culture did not express
VEGFRs, whereas they did in vivo [13]. Therefore, new and/or en-
hanced oncogenetic signaling, which DaoyHER2 xenografts rely on,
could sensitize them to AEE788’s inhibitory effects. Factors in the tumor
microenvironment, such as cytokines or hypoxia, might upregulate
VEGFR2 expression, with molecular mechanisms similar to those de-
scribed for VEGF [30].
The nonendothelial VEGFR2 expression that has been observed in
cell lines and biopsy specimens of different cancers, including medullo-
blastoma, implies a role for VEGFR2 beyond neovascularization
[16,31,32]. In vitro, the VEGF/VEGFR2 systemmediates proliferation
of medulloblastoma cells [16]. Also, in human medulloblastoma, the
concomitant expression of VEGF and receptors in tumor cells suggests
that VEGFR2mediates amitogenic stimulus in response toVEGF [16].
Neoangiogenesis has been correlated with HER2 expression in sur-
gical samples of breast cancer [9]. The correlation that we found be-
tween the expression of HER2 and that of the angiogenesis-related
genes VEGF, VEGFR2, and bFGF is a novel finding in clinical me-
dulloblastoma and hints at HER2 eliciting an angiogenic signal also
in this tumor. However, the lack of correlation between HER2 and
VEGFR1 suggests that the HER2-associated VEGFR2 pathway could
be related not only to newly formed vessels but also to tumor cells.
Indeed, VEGFR2 mediates mitogenesis and survival signaling, whereas
VEGFR1 plays a “decoy” function by sequestering VEGF and prevent-
ing its interaction with VEGFR2 [6]. Of interest, kinome profiling
in pediatric brain tumors revealed a consistent activation of VEGFR2
only in the medulloblastoma samples, which suggests a relevant role
for this signaling specifically in this tumor [33].
In summary, we have provided experimental evidence that block-
ade of HER and VEGFR signaling pathways by AEE788 might have
a therapeutic potential in medulloblastoma, mostly in those overexpres-
sing HER2. However, identification of other molecular correlates of
AEE788 responsiveness is warranted to prospectively identify tumors
that are more likely to benefit from AEE788 treatment.
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